Literature DB >> 3593431

Immunologic studies of rheumatoid arthritis patients treated with methotrexate.

N J Olsen, L F Callahan, T Pincus.   

Abstract

Immunologic functions of peripheral blood mononuclear cells were studied in rheumatoid arthritis (RA) patients treated with methotrexate (MTX). Spontaneous IgM rheumatoid factor (IgM-RF) synthesis by unstimulated cultured blood mononuclear cells was seen in only 3 of 18 MTX-treated patients, compared with 31 of 54 RA patients who were not receiving long-acting drugs. Total IgM production by unstimulated cultured mononuclear cells, pokeweed mitogen-induced antibody synthesis, and plasma levels of IgM-RF were also lower in MTX-treated patients than in other RA patients. The numbers of circulating B cells, T4 and T8 cells, the T4:T8 cell ratio, and mitogen-induced proliferation indices were similar in MTX-treated and non-MTX-treated patients. Eleven additional patients were studied prospectively after initiation of MTX therapy. All showed significant decreases in spontaneous IgM-RF synthesis, with declining IgM-RF:IgM ratios, including all of the 9 who were studied during the first 24 hours of treatment. The results indicate that MTX has rapid effects on IgM-RF synthesis, and this action might be associated with its therapeutic efficacy in RA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593431     DOI: 10.1002/art.1780300501

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  24 in total

Review 1.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 2.  New approaches to the treatment of rheumatoid arthritis.

Authors:  P A Miescher; Y P Huang; R H Zubler
Journal:  Springer Semin Immunopathol       Date:  1988

3.  Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism.

Authors:  Addolorata Corrado; Anna Neve; Arcangela Marucci; Annamaria Gaudio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2014-08-23       Impact factor: 3.984

Review 4.  Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent?

Authors:  S Tariq; S M Tariq
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

5.  Folate supplementation and methotrexate.

Authors:  S L Morgan; J E Baggott; W J Koopman; C L Krumdieck; G S Alarcón
Journal:  Ann Rheum Dis       Date:  1993-04       Impact factor: 19.103

Review 6.  New perspectives of secondary and tertiary therapy for rheumatoid arthritis.

Authors:  R F Willkens
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis.

Authors:  N J Olsen; G P Teal; R H Brooks
Journal:  Agents Actions       Date:  1991-09

8.  Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma.

Authors:  L M Kuitert; A C Harrison
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

Review 9.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs.

Authors:  G W Lu; H W Jun; M T Dzimianski; H C Qiu; J W McCall
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.